Application
Quantification of Risankizumab
Specific labelling
Arginine: 13C6,15N4>99%
Lysine: 13C6,15N2, >99%
Description
Risankizumab (Skyrizi) is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Use in treatment of moderate to severe plaque psoriasis, moderate to severe Crohn's disease, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an inadequate response to conventional therapies.
This product is for research use only and is not intended for diagnostic or therapeutic use.
For any quantities, please contact us
Custom clearance and freight insurance costs to be borne by the customer.
This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only. Information about licenses for other uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.com.
